Holen Sie sich die Stockscreener-App
289.33
0.09%
0.5025
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued? - simplywall.st
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book - Yahoo Finance
Ligand (NASDAQ: LGND) insider to sell 15,000 shares after plan trades - Stock Titan
XOMA Royalty Reports $41.2M First-Half Net Loss on Trial Failures - Minichart
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
A cash-heavy royalty arm at Ligand (NASDAQ: LGND) is loss-making - Stock Titan
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale By Investing.com - Investing.com Canada
Ligand to Participate in September Investor Conferences - marketscreener.com
Ligand (LGND) Snapshot: Ends Down by 2.13% at $280.18 for the Current Session; Price Setup: the Supplied Trading Band Runs From $266.17 to $294.19 at the CloseEarnings Breakout Stocks - vinanet.vn
Ligand (LGND) Chart: Retreats 0.38% to $286.29 in Latest Trading; Chart Watch: $271.98 and $300.60 Define the Nearby Reference Levels in the Available RecordMomentum Trade - vinanet.vn
$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga
LGND6487833 Bond Profile — Key Metrics - TradingView
LGND6487833 Bond Yield and Price — FINRA:LGND6487833 - TradingView
Enterprise value to revenue forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand (LGND) Q2 2026 Earnings Call Transcript - AOL.com
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague - Fierce Biotech
Bank of America Corp DE Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals(LGND.US) Officer Sells US$9.24 Million in Common Stock - Moomoo
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Haas Sells 7,138 Shares - MarketBeat
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells 31,641 Shares of Stock - MarketBeat
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares - Investing.com South Africa
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares By Investing.com - Investing.com UK
Ligand Pharmaceuticals (LGND) director exercises options and sells 7,138 shares - Stock Titan
LGND Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Leerink Partners - MarketBeat
Stifel reiterates Buy on Ligand Pharma stock, $332 target By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run - Yahoo Finance
Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced? - Yahoo Finance
Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals - Stock Titan
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
LIGAND PHARMACEUTICALS INC SEC Filing (Aug 12, 2026) - Stock Titan
Ligand (NASDAQ: LGND) holder Jason Haas files Form 144 for stock sale - Stock Titan
Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390 - Moomoo
Q1 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q4 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ligand Pharmaceuticals (LGND) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
LGND: XOMA Acquisition Closed - Smartkarma
Weekly Recap: Q2 revenue, royalty growth and $700M convertible notes - TradingView
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Issues Quarterly Earnings Results - MarketBeat
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370 - moomoo.com
California State Teachers Retirement System Acquires 4,987 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
LGND SWOT Analysis: Strong Revenue Growth Amidst Valuation Conce - GuruFocus
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $370 - Moomoo
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345 - Moomoo
Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $326 - Moomoo
Ligand Pharmaceuticals (LGND) Releases Q2 2026 Earnings: Revenue Declines but EPS Jumps - Quiver Quantitative
LGND Maintained by RBC Capital -- Price Target Raised to $345 - GuruFocus
Ligand Pharmaceuticals 2Q 2026: Revenue $63.69M, EPS $2.22— 10-Q Summary - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) lifts Q2 net income to 48,508 - Stock Titan
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):